Hase · Journal of neurochemistry 2018 · narrative review · n=?

White matter degeneration in vascular and other ageing-related dementias.

Cited 209 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review of pathophysiology, imaging, and preclinical models without systematic search or meta-analysis.

PubMed 29210074 · doi:10.1111/jnc.14271 · record verified 2026-08-30

What was done

This review synthesized neuroimaging characteristics, cellular pathology, and preclinical models related to white matter degeneration in vascular dementia and Alzheimer's disease. The authors examined pathological substrates—including leukoaraiosis and magnetic resonance imaging white matter hyperintensities—cellular disruption within the gliovascular unit (astrocytes, oligodendrocytes, microglia, pericytes), hemodynamic mechanisms of deep white matter chronic hypoxia, and pharmacological compounds tested to mitigate blood-brain barrier damage, oxidative stress, and inflammation.

What was found

The abstract provides no quantitative data or effect sizes. Key qualitative pathological alterations described include myelin loss, axonal abnormalities, arteriolosclerosis, lacunar infarcts, microbleeds, and dilated perivascular spaces. At the cellular level, early changes involve oligodendrocyte loss and astrocytic clasmatodendrosis accompanied by aquaporin 4 displacement, which precede microvascular degeneration, blood-brain barrier leakage, and deep white matter edema. Preclinical testing of various compounds yielded variable efficacy, leading the authors to conclude that single-target therapies are insufficient to address the multiple substrates of white matter degeneration.

Why it matters

The review emphasizes that white matter damage across age-related dementias is not driven by a single pathway but reflects complex failure of the gliovascular unit under chronic hypoperfusion. This framework indicates that preserving cognitive function in vascular and mixed dementias will require multimodal or combination therapeutic strategies.

Limits

This is a narrative review that does not report systematic search methods, screening criteria, or quantitative data synthesis. Specific animal models, drug classes, dosages, and human clinical trial outcomes are not detailed in the abstract, preventing independent evaluation of comparative drug efficacy or clinical translation.

Cited by